Table of Contents
- Trial overview
- Who participated
- Trial phases and study design
- What the trials measured
- Study treatments and comparisons
- Key points for patients
Trial overview
Two interventional studies investigated Ulonivirine in people with HIV or HIV-1 infection.[1][2] One study was completed and one was authorised, showing that research is looking at both earlier and later stages of development.[1][2]
The completed study, NCT04564547, was a Phase 2 dose-ranging and switch study in HIV-1 infection.[1] The authorised study, 2025-522519-40-00, is a clinical study of islatravir and Ulonivirine for people with HIV-1 who have not been treated before.[2]
Who participated
The completed Phase 2 study included 161 participants with HIV-1 infection.[1] This study also compared study treatment with standard HIV treatment options, which suggests it included people already living with HIV and being considered for a switch in treatment.[1]
The authorised study plans to enroll 520 participants with HIV, and it focuses on people who have not been treated before.[2] This target group is important because it helps researchers see how the study treatment works as a first HIV treatment plan.[2]
Trial phases and study design
Phase 2 studies usually look at early signs of benefit and safety in a smaller group of people.[1] In the completed study, researchers reviewed the accumulated safety data for a once-weekly treatment plan.[1]
The authorised study includes both Phase 2 and Phase 3 parts, so it is designed to first check early results and then confirm them in a larger group.[2] The study compares islatravir and Ulonivirine once weekly with a standard daily treatment, BIC/FTC/TAF.[2]
Both studies are interventional, which means researchers assigned the treatment plans and then measured outcomes over time.[1][2]
What the trials measured
The completed study focused on safety and tolerability, including the percentage of participants with at least one adverse event and the percentage who stopped the study treatment because of an adverse event.[1] An adverse event is any unwanted medical problem that happens during a study.[1]
The authorised study measures HIV-1 RNA levels in the blood, using the goal of less than 50 copies/mL at Week 24 and Week 48.[2] Lower HIV-1 RNA means the virus is better controlled.[2]
That study also measures adverse events and whether participants discontinue the study intervention because of an adverse event at Week 24 and Week 48.[2] These outcomes help show both how well the treatment works and how easy it is for people to stay on it.[2]
Study treatments and comparisons
In the completed Phase 2 study, Ulonivirine was studied with islatravir and compared against placebo versions of study drugs and against BIC/FTC/TAF, which is a standard HIV treatment combination listed in the trial data.[1] The study also included a once-weekly approach, which is part of what researchers were testing.[1]
In the authorised study, Ulonivirine is studied with islatravir as a once-weekly plan and compared with BIC/FTC/TAF given once daily.[2] The trial data also show placebo groups for some study components, which helps researchers compare results fairly.[2]
Key points for patients
These trials are not general information studies; they are testing specific HIV treatment plans that include Ulonivirine.[1][2] The main goals are to see whether the treatment can control HIV and whether people can take it safely over time.[1][2]
The trial data show two important groups: people with HIV-1 infection in a switch study and people with HIV who have not been treated before.[1][2] Together, these studies help researchers understand how Ulonivirine may fit into HIV treatment research.[1][2]
